PubMed · 14853166
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
W E HENLEY. 1951. Fatigue.. https://pubmed.ncbi.nlm.nih.gov/14853166/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Profound fatigue is a clinically significant complication of chronic liver disease. A mechanism of fatigue in experimental animals and male athletes appears to be increased serotoninergic neurotransmission in the brain. Recently, attempts have been made to assess the efficacy of a serotonin antagonist, specifically the 5-HT3 receptor subtype antagonist, ondansetron, in ameliorating fatigue in patients with chronic liver disease. However, the results of a randomized controlled trial of ondansetron for fatigue in patients with primary biliary cirrhosis did not indicate that ondansetron was either effective or ineffective. The reasons for the uncertain outcome of the randomized controlled trial are not clear. One contributing factor may have been the use of subjective indices of fatigue as primary efficacy endpoints. There is a need to develop objective quantitative primary efficacy endpoints for use in trials of therapy for fatigue. Another contributing factor may relate to the conduct of a randomized controlled trial not invariably being the optimal approach to resolve a specific clinical issue, particularly when the application of statistical methods yields equivocal findings. When the results of a randomized controlled trial are indecisive, findings based on clinical judgement, medicine's most important asset, should be carefully evaluated.
Fatigue is often experienced after liver transplantation. The aim of this cross-sectional study was to assess the severity of fatigue in liver transplant recipients. In addition, the nature of fatigue and factors that may be associated with severity of fatigue after liver transplantation were explored. Ninety-six patients up to 15 years after liver transplantation were included. Severity of fatigue and nature of fatigue were assessed with the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory, respectively. Furthermore, age, gender, indication for transplantation, time since transplantation, immunosuppressive medication, self-experienced disability, and health-related quality of life (HRQoL) were assessed as potential associated factors. Sixty-six percent of all patients was fatigued (FSS > or = 4.0) and 44% of all patients was severely fatigued (FSS > or = 5.1). Patients experienced physical fatigue and had reduced activity rather than mental fatigue and reduced motivation. Age, gender, self-experienced disabilities, and HRQoL were correlated with severity of fatigue. Results of the study indicate that fatigue is a major problem in patients after liver transplantation and no indications were found that complaints of fatigue improve over time. Liver transplant recipients experience physical fatigue and reduced activity rather than mental fatigue and reduced motivation. These findings have implications for the development of interventions needed to rehabilitate persons after liver transplantation.